Statistical Analysis Report (SAR)

Survival analysis of events attributed to PJI in patients that undergone TJA surgeries

DOCUMENT: SAR-2021-001-LT-v01

From: Felipe Figueiredo To: Lucio Toledo

Date: 2021-04-11

TABLE OF CONTENTS

1 ABBREVIATIONS	2
2 INTRODUCTION	2
2.1 Objectives	2
2.2 Data reception and cleaning	2
3 METHODS	3
3.1 Variables	3
3.1.1 Outcome and time definition	3
3.1.2 Covariates	3
3.2 Statistical analyses	3
3.2.1 Statistical packages	3
4 RESULTS	4
4.1 Study population and follow up	4
4.2 Mortality	4
4.3 2-year survival rates	6
5 EXCEPTIONS AND OBSERVATIONS	9
6 CONCLUSIONS	9
7 REFERENCES	9
8 APPENDIX	9
8.1 Exploratory data analysis	9
8.2 Alternative results table	17

FF Consultoria em Bioestatística e Epidemiologia	Version	Year	Page	
CNPJ: 42.154.074/0001-22	SAR			_
1.1. //1: 1. /66 . 1		1	2021	1 / 18

Statistical Analysis Report (SAR)

8.3 Availability	. 18
8.4 Analytical dataset	. 18

Document version

Version	Alterations
01	Initial version

1 ABBREVIATIONS

- PJI:
- SD: standard deviation
- SIRS: systemic inflammatory response
- TJA:

2 INTRODUCTION

2.1 Objectives

Perform a Kaplan-Meier survival analysis on the deaths caused by PJI after a TJA surgical procedure. Additionally, explore possible risk factor for PJI mortality in bi-variate analyses.

2.2 Data reception and cleaning

Analytical data-set

- 1. ID
- 2. Age; continuous
- 3. Sex; binary
- 4. time (date PJI diagnosis date last follow up)
- event (death due to PJI)
- 6. death (all causes)
- 7. Joint; binary
- 8. SIRS; binary
- 9. Multi-germ infection; binary
- 10. Complication; binary
- 11. Surgery type; categorical
- 12. Surgery success; binary

FF Consultoria em Bioestatística e Epidemiologia		Version	Year	Page
CNPJ: 42.154.074/0001-22	SAR			
https://linktr.ee/ff.epi.biostat		1	2021	2 / 18

Statistical Analysis Report (SAR)

Obs: Complication Type was considered for analysis, but could not be safely converted to a categorical variable. It was dropped.

3 METHODS

3.1 Variables

3.1.1 Outcome and time definition

The event of interest for this analysis is death caused by the PJI. For the main analysis patients that died from other causes were censored. The time to event was defined as the number of years between the diagnosis of PJI and the last follow up noted.

There were multiple outcomes to consider regarding the mortality in PJI patients. These causes were categorized as being caused by PJI (event of interest), other causes of death and survival (censored). This multi-state outcome was used to assess the competing risks of death under the PJI risk. The follow up time of all participants was considered in the person-year at risk.

3.1.2 Covariates

- Sex; binary
- Joint; binary
- Complication; binary
- SIRS; binary
- Multi-germ infection; binary
- Surgery success; binary
- Surgery type; categorical

3.2 Statistical analyses

Demographic characteristics were described with mean (SD) or proportions, where appropriate. Kaplan-Meier curves were computed for the at-risk study population for the event of interest. For all covariates considered the 2-year survival rates were computed for the event of interest. The all-cause mortality was assessed using the competing risks overall figure. Bi-variate analyses were performed using the log-rank test for all covariates considered. All statistical analyses considered the significance level of 5%.

3.2.1 Statistical packages

This analysis was performed using statistical software R version 4.0.5. Packages used for survival analyses were survival version 3.2.10 and survminer version 0.4.9.

FF Consultoria em Bioestatística e Epidemiologia		Version	Year	Page
CNPJ: 42.154.074/0001-22	SAR			_
https://linktr.ee/ff.epi.biostat		1	2021	3 / 18

Statistical Analysis Report (SAR)

4 RESULTS

4.1 Study population and follow up

Of the 54 participants were included, 21 (39%) were male and 33 (61%) were female. Average (SD) age was 64.3 (11.6) years, ranging from 32 to 88 years. Time under observation ranged from 4 days to 16.35 years, where all 54 participants contributed with a total of 239 person-years of follow up.

4.2 Mortality

44 of the 54 patients survived until the last follow up observation. Of the deaths recorded, 5 from other causes and 5 could be attributed to PJI (Fig 1). All deaths attributed to PJI occurred before the deaths unrelated. Figure 2 shows the Kaplan-Meier estimate of the mortality rate attributed to PJI. Times of death ranged from 4 days to 2.13 years. The survival rate at the end of study follow up was 89.7% so the median time of survival could not be estimated. The 1-year survival rate was estimated as 96% (91% – 100%) and the 2-year survival rate was estimated as 92% (85% – 100%).

Times of deaths unrelated to PJI ranged from 2.37 years to 13.17 years (Fig 1). It is noticeable that, while this analysis does not give proof that there is a significant difference between times of death between all causes, this sample seem to indicate that most patients die from PJI within 2 years of the diagnosis (Fig 2).

FF Consultoria em Bioestatística e Epidemiologia		Version	Year	Page
CNPJ: 42.154.074/0001-22	SAR			
https://linktr.ee/ff.epi.biostat		1	2021	4 / 18

Statistical Analysis Report (SAR)

Competing risks for causes of death after TJA




Figure 1 Mortality due to all causes.

FF Consultoria em Bioestatística e Epidemiologia		Version	Year	Page
CNPJ: 42.154.074/0001-22	SAR			
https://linktr.ee/ff.epi.biostat		1	2021	5 / 18

Statistical Analysis Report (SAR)




Figure 2 Mortality confirmed to be caused by PJI.

4.3 2-year survival rates

Table 1 shows the 2-year survival rates across all covariates considered. In this sample surgical complications decreased the survival (log-rank p=0.038), and most events were related to the procedure of Spacer, where the median time of survival was 3.14 weeks (log-rank p=0.002).

FF Consultoria em Bioestatística e Epidemiologia		Version	Year	Page
CNPJ: 42.154.074/0001-22	SAR			_
https://linktr.ee/ff.epi.biostat		1	2021	6 / 18

Statistical Analysis Report (SAR)

Table 1 Survival rates for 2-year.

Characteristic	2-year survival	P
Overall	92% (85%, 100%)	
Sex		0.275
F	93% (85%, 100%)	
М	90% (79%, 100%)	
Joint		0.703
Hip	92% (83%, 100%)	
Knee	92% (82%, 100%)	
Complication		0.038
N	100% (100%, 100%)	
Y	82% (68%, 100%)	
SIRS		0.056
N	97% (92%, 100%)	
Y	77% (57%, 100%)	
Multigerm		0.938
N	92% (84%, 100%)	
Y	92% (77%, 100%)	
surg.success		0.060
Failure	84% (67%, 100%)	

FF Consultoria em Bioestatística e Epidemiologia		Version	Year	Page
CNPJ: 42.154.074/0001-22	SAR		_	
https://linktr.ee/ff.epi.biostat		1	2021	7 / 18

Statistical Analysis Report (SAR)

Success	100% (100%, 100%)	
surg.type		0.002
Amputation	— (—, —)	
Arthrodesis	100% (100%, 100%)	
Exarticulation	100% (100%, 100%)	
Girdlestone	67% (30%, 100%)	
Spacer	50% (19%, 100%)	
TJA	97% (93%, 100%)	

Although a significant difference in the status of surgery success was not detected it could be possible that there is a true association between these predictos. This variable had 18 missing values in the sample that were dropped from the analysis. Oh the other hand the effect of a surgical complication is strong enough to be detected even in the presence of 13 missing values in the sample.

FF Consultoria em Bioestatística e Epidemiologia		Version	Year	Page
CNPJ: 42.154.074/0001-22	SAR			
https://linktr.ee/ff.epi.biostat		1	2021	8 / 18

Statistical Analysis Report (SAR)

- **5 EXCEPTIONS AND OBSERVATIONS**
- 6 CONCLUSIONS
- 7 REFERENCES
- 8 APPENDIX
- 8.1 Exploratory data analysis

FF Consultoria em Bioestatística e Epidemiologia		Version	Year	Page
CNPJ: 42.154.074/0001-22	SAR			
https://linktr.ee/ff.epi.biostat		1	2021	9 / 18

Statistical Analysis Report (SAR)

Survival by Sex




Figure A1 Mortality by Sex.

FF Consultoria em Bioestatística e Epidemiologia		Version	Year	Page
CNPJ: 42.154.074/0001-22	SAR			
https://linktr.ee/ff.epi.biostat		1	2021	10 / 18

Statistical Analysis Report (SAR)

Survival by operated Joint






Figure A2 Mortality by joint.

FF Consultoria em Bioestatística e Epidemiologia		Version	Year	Page
CNPJ: 42.154.074/0001-22	SAR			_
https://linktr_ee/ff_epi_biostat		1	2021	11 / 18

Statistical Analysis Report (SAR)

Survival given Complications





Figure A3 Mortality under presence of surgical complication.

FF Consultoria em Bioestatística e Epidemiologia		Version	Year	Page
CNPJ: 42.154.074/0001-22	SAR			
https://linktr.ee/ff.epi.biostat		1	2021	12 / 18

Statistical Analysis Report (SAR)

Survival given multi-germ infection






Figure A4 Mortality by Multi-germ.

FF Consultoria em Bioestatística e Epidemiologia		Version	Year	Page
CNPJ: 42.154.074/0001-22	SAR			
https://linktr.ee/ff.epi.biostat		1	2021	13 / 18

Statistical Analysis Report (SAR)

Survival by Confirmed SIRS




Figure A5 Mortality by SIRS.

FF Consultoria em Bioestatística e Epidemiologia		Version	Year	Page
CNPJ: 42.154.074/0001-22	SAR			_
https://linktr_ee/ff_epi_biostat		1	2021	14 / 18

Statistical Analysis Report (SAR)

Survival by surgery success




Figure A6 mortality by status of the TJA.

FF Consultoria em Bioestatística e Epidemiologia		Version	Year	Page
CNPJ: 42.154.074/0001-22	SAR			
https://linktr.ee/ff.epi.biostat		1	2021	15 / 18

Statistical Analysis Report (SAR)

Survival by surgery type




Figure A7 Mortality by surgery outcome.

FF Consultoria em Bioestatística e Epidemiologia		Version	Year	Page
CNPJ: 42.154.074/0001-22	SAR			_
https://linktr.ee/ff.epi.biostat		1	2021	16 / 18

Statistical Analysis Report (SAR)

8.2 Alternative results table

Table 2 Optional version of Table 1, adding 1-year survival rates.

Characteristic	1-year survival	2-year survival	Р
Overall	96% (91%, 100%)	92% (85%, 100%)	
Sex			0.275
F	100% (100%, 100%)	93% (85%, 100%)	
М	90% (79%, 100%)	90% (79%, 100%)	
Joint			0.703
Hip	96% (89%, 100%)	92% (83%, 100%)	
Knee	96% (89%, 100%)	92% (82%, 100%)	
Complication			0.038
N	100% (100%, 100%)	100% (100%, 100%)	
Υ	92% (81%, 100%)	82% (68%, 100%)	
SIRS			0.056
N	100% (100%, 100%)	97% (92%, 100%)	
Y	85% (67%, 100%)	77% (57%, 100%)	
Multigerm			0.938
N	98% (93%, 100%)	92% (84%, 100%)	
Υ	92% (77%, 100%)	92% (77%, 100%)	
surg.success			0.060

FF Consultoria em Bioestatística e Epidemiologia		Version	Year	Page
CNPJ: 42.154.074/0001-22	SAR			
https://linktr.ee/ff.epi.biostat		1	2021	17 / 18

Statistical Analysis Report (SAR)

Failure	93% (80%, 100%)	84% (67%, 100%)	
Success	100% (100%, 100%)	100% (100%, 100%)	
surg.type			0.002
Amputation	100% (100%, 100%)	— (—, —)	
Arthrodesis	100% (100%, 100%)	100% (100%, 100%)	
Exarticulation	100% (100%, 100%)	100% (100%, 100%)	
Girdlestone	100% (100%, 100%)	67% (30%, 100%)	
Spacer	50% (19%, 100%)	50% (19%, 100%)	
ALT	100% (100%, 100%)	97% (93%, 100%)	

8.3 Availability

This document can be downloaded in the following address:

https://github.com/philsf-biostat/SAR-2021-001-LT/

8.4 Analytical dataset

Due to confidentiality the data-set used in this analysis cannot be shared online in the public version of this report.

Table A1 Analytical dataset structure

id	Age	Sex	time	event	death	Joint	Complication	SIRS	Multigerm	surg.type	surg.success
1											
2											
3											
54											